Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis

Krzysztof Karnicki; Robert J. Leadley Jr.; Sangita Baxi; Thomas Peterson; Waldemar Wysokinski; Robert D. McBane II

doi:10.1160/TH07-09-0576

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2008; 99(04): 759-766
DOI: 10.1160/TH07-09-0576

Animal Models

Schattauer GmbH

Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis

Krzysztof Karnicki

²Section of Hematology Research Mayo Clinic, Rochester, Minnesota, USA

,

Robert J. Leadley Jr.

³Cardiovascular Biology, Pfizer Global Research and Development, Ann Arbor, Michigan, USA

,

Sangita Baxi

³Cardiovascular Biology, Pfizer Global Research and Development, Ann Arbor, Michigan, USA

,

Thomas Peterson

³Cardiovascular Biology, Pfizer Global Research and Development, Ann Arbor, Michigan, USA

,

Waldemar Wysokinski

¹Division of Cardiology

²Section of Hematology Research Mayo Clinic, Rochester, Minnesota, USA

,

Robert D. McBane II

¹Division of Cardiology

²Section of Hematology Research Mayo Clinic, Rochester, Minnesota, USA

› Institutsangaben

Abstract

Summary

The objective of this study was to determine if orally-administered PD0348292, a direct specific factor Xa inhibitor, inhibits thrombosis following porcine carotid arterial injury comparably to aspirin or clopidogrel alone or in combination. We further sought to determine whether the antithrombotic efficacy in vivo could be predicted using an ex-vivo perfusion chamber. Oral treatments included: PD0348292 (0.4, 0.9, or 4.3 mg/kg); PD0348292 (0.4 mg/kg) plus aspirin (325 mg); aspirin; clopidogrel (75 mg); aspirin plus clopidogrel; or vehicle (n=6–10/group). Aspirin and clopidogrel were administered 27 and four hours pre-injury and PD0348292 or vehicle was administered four hours pre-injury. Both carotid arteries were crush-injured, and thrombus was measured by detection of 111In-platelets over 30 minutes. Prior to injury, the antithrombotic efficacy was assessed by ex-vivo perfusion chamber platelet deposition. PD0348292 produced dose-dependent prothrombin time (0.9- to 2.9-fold) and aPTT (1.4- to 2.5-fold) prolongations. Bleeding times were significantly prolonged in each active drug group compared to vehicle, but were not significantly different between drug groups. PD0348292 significantly inhibited arterial platelet deposition (x106/cm2) at 4.3(549 ± 1,066), 0.9 (399 ± 162) and 0.4 mg/kg (531 ± 470) compared to vehicle (2,242 ± 1,443). Aspirin (992 ± 973), clopidogrel (537 ± 483), clopidogrel plus aspirin (228 ± 66) or PD0348292 plus aspirin (558 ± 317) also significantly inhibited platelet deposition, although these values were not significantly different than with any dose of PD348292. Perfusion chamber platelet deposition correlated significantly with in-vivo anti-thrombotic response. In conclusion, PD0348292 inhibited arterial thrombosis comparable to aspirin plus clopidogrel. Perfusion chamber methodology may be useful in predicting in-vivo antithrombotic efficacy.

Keywords

Thrombosis - platelets - anticoagulants - factor Xa

Volltext

Referenzen

References
1 Fuster V, Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology. Circulation 1994; 90: 2126-2146.
2 Smith SC, Jr Allen J, Blair SN. et al. AHA/ACC. National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113: 2363-2372.
3 McBane RD, Wysokinski WE, Chesebro JH. et al. Antithrombotic action of endogenous porcine protein C activated with latent porcine thrombin preparation. Thromb Haemost 1995; 74: 879-885.
4 Owen WG, Bichler J, Ericson D. et al. Gating of thrombin in platelet aggregates by pO2-linked lowering of extracellular [Ca2+]. Biochemistry 1995; 34: 9277-9281.
5 Wysokinski W, McBane RD, Chesebro J. et al. Reversibility of platelet thrombosis in vivo. Quantitative analysis in porcine carotid arteries. Thromb Haemost 1996; 76: 1108-1113.
6 Karnicki K, McBane RD, Miller RS. et al. Inhibition and reversal of platelet-rich arterial thrombus in vivo: Direct vs indirect factor Xa inhibition. J Thromb Haemost 2004; 2: 2162-2169.
7 Zafar MU, Farkouh ME, Osende J. et al. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients. Thromb Haemost 2007; 97: 487-492.
8 Orvim U, Barstad RM, Vlasuk GP. et al. Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis. Arterioscler Thromb Vasc Biol 1995; 15: 2188-2194.
9 Shimbo D, Osende J, Chen J. et al. Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin. Thromb Haemost 2002; 88: 733-738.
10 Eriksson H, Wahlander K, Gustafsson D. et al. Thrive Investigators. A randomized, controlled, doseguiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003; 1: 41-47.
11 Olsson SB. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362: 1691-1698.
12 Eriksson BI, Dahl Buller HR. et al. BISTRO II Study Group. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3: 103-11.
13 Eriksson BI, Quinlan DJ. Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Drugs 2006; 66: 1411-1429.
14 Kohrt JT, Bigge CF, Bryant JW. et al. The discovery of PD0348292, an orally efficacious Factor Xa inhibitor. The discovery of (2R,4R)-N-(4-chlorophenyl)- N- (2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)- 4-methoxypyrrolidine-1,2-dicarboxamide (PD 0348292), an orally efficacious factor Xa inhibitor. Chem Biol Drug Des 2007; 70: 100-112.
15 Wysokinski WE, McBane RD, 2nd. Owen WG. Individual propensity for arterial thrombosis. Arterioscler Thromb Vasc Biol 1999; 19: 883-886.
16 Albers GW, Amarenco P, Easton JD. et al. Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 483S-512S.
17 The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 1997; 349: 1569-1515.
18 The Chinese Acute Stroke Trial (CAST): randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Collaborative Group. Lancet 1997; 349: 1641-1649.
19 Mas JL, Chatellier G, Beyssen B. et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 2006; 355: 1660-1671.
20 Gould WR, Cladera E, Harris MS. et al. Co-crystal structure and inhibition of factor Xa by PD0313052 identifies structurally stabilized active site residues of factor Xa and prothrombinase. Biochemistry 2005; 44: 9280-9289.
21 Karnicki K, Komorowicz E, Fass DN. et al. Influence of anatomical location on arterial thrombosis. Arterioscler Thromb Vasc Biol 2002; 22: 342-347.
22 Badimon L, Badimon JJ, Galvez A. et al. . Influence of arterial damage and wall shear rate on platelet de-position: ex vivo study in a swine model. Arteriosclerosis 1986; 6: 312-320.
23 Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Brit Med J 2002; 324: 71-86.
24 Gum PA, Kottke-Marchant K, Welsh PA. et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-965.
25 Macchi L, Christiaens L, Brabant S. et al. Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. J Am Coll Cardiol 2003; 42: 1115-1119.
26 Mueller MR, Salat A, Stangl P. et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78: 1003-1007.
27 Eikelboom JW, Hirsh J, Weitz JI. et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-1655.
28 Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993; 71: 397-403.
29 Gurbel PA, Bliden KP, Hiatt BL. et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
30 Matetzky S, Shenkman B, Guetta V. et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
31 Wiviott SD, Antman EM. Clopidogrel resistance: a new chapter in a fast-moving story. Circulation 2004; 109: 3064-3067.
32 Alexander JH, Singh K. Inhibition of Factor Xa: A potential target for the development of new anticoagulants. Amer J Cardio Drugs 2005; 5: 279-290.
33 Yusuf S, Zhao F, Mehta SR. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.